Clinical Manifestations of Intraocular Lymphoma. |
Min Hee Suh, Hyeong Gon Yu |
1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea. hgonyu@snu.ac.kr 2Institute of Sensory Organs, Medical Research Center, Seoul National University, Seoul, Korea. 3Institute of Rheumatology, Medical Research Center, Seoul National University, Seoul, Korea. |
원발성 안구내 림프종의 임상 양상과 진단 및 치료 |
서민희1ㆍ유형곤1-3 |
Department of Ophthalmology, Seoul National University College of Medicine1, Seoul, Korea / Institute of Sensory Organs, Medical Research Center, Seoul National University2, Seoul, Korea / Institute of Rheumatology, Medical Research Center, Seoul National University3, Seoul, Korea |
|
Abstract |
PURPOSE To investigate the clinical features and prognosis of primary intraocular lymphoma (PIOL). METHODS: A retrospective review of medical records was performed in 9 patients who were diagnosed and treated as PIOL in the Department of Ophthalmology, Seoul National University Hospital. RESULTS: Among patients who were enrolled in the study, 14 eyes were examined. Thirteen eyes (92.9%) showed yellowish subretinal or choroidal infiltrates which is a characteristic finding of PIOL in fundus examination and fluorescein angiography. Three patients presented with ocular symptoms initially, and 5 patients later presented with central nerve system (CNS) involvement. Only 1 patient showed PIOL without CNS involvement. Among 6 patients (9 eyes) that received systemic chemotherapy or ocular irradiation, 5 patients (7 eyes, 77.8%) responded. Among those patients, 3 patients (4 eyes) showed relapse of PIOL. Five patients died during the mean follow-up period of 43.3 months, and the median survival time was 47 months. CONCLUSIONS: The most common characteristic fundus finding of PIOL is subretinal or choroidal infiltration. Ocular irradiation combined with systemic chemotherapy is the first method of treatment, although long-term prognosis is poor. |
Key Words:
Primary central nervous system lymphoma;Primary intraocular lymphoma;Prognosis;Subretinal or choroidal infiltration;Vitreous biopsy |
|